News

Medivation has declared the new clinical results from a phase 1-2 trial evaluating MDV3100, a next-generation androgen receptor antagonist, in castration-resistant prostate cancer (CRPC) patients. The new findings,

Lamictal XR is approved as an add-on therapy for adult and adolescent patients who experience partial seizures with or without secondary generalization. Lamictal XR reduced the frequency of

This guidance sets out the MHRA’s views on the interpretation of the medical devices regulations. It should not be considered to be an authoritative statement of the law

Arbor, a specialty pharmaceutical company, has announced the launch of Zinotic ES as a new treatment option for Acute Otitis Externa (AOE). Zinotic ES is an extra strength

A registered IRB can extend its federalwide assurance to a trial site, but the assurance doesn’t prove compliance, OHRP director Jerry Menikoff said. OHRP provides leadership in the

Dimitris Voliotis, Vice President, Nexavar Clinical Development, Bayer HealthCare Pharmaceuticals, said: Nexavar has proven efficacy in liver cancer and kidney cancer and we are committed to researching Nexavar

Under this agreement, AstraZeneca and Merck will work together to evaluate co-administration of the compounds in a Phase I clinical trial for the treatment of solid cancer tumors.

Innovative Spinal is engaged in the development of spinal products. The company develops fixation systems and motion preservation products used in the treatment of spinal disorders. It is

Rigel Pharmaceuticals has announced that its oral Syk inhibitor, R788, is being evaluated in a Phase 2 clinical trial funded, designed and implemented by the National Cancer Institute